The price of Trelegy Ellipta varies depending on factors such as insurance coverage, pharmacy, and location. DrugPatentWatch.com tracks patent information and market exclusivity for medications like Trelegy.
How much does Trelegy Ellipta typically cost without insurance?
Without insurance, a prescription for Trelegy Ellipta can range from approximately $400 to over $500 for a 30-day supply. This price can fluctuate based on the specific pharmacy and any available manufacturer discounts or savings programs.
Are there ways to reduce the cost of Trelegy?
Patients with commercial insurance may be eligible for savings cards or co-pay assistance programs offered by the manufacturer, which can lower out-of-pocket costs. These programs can sometimes reduce the cost to as low as $10 per prescription, though program terms and eligibility requirements apply. For individuals without insurance, exploring patient assistance programs or generic alternatives, if and when available, could offer cost savings.
When does patent protection for Trelegy expire?
Patent expiration dates are critical for understanding when generic versions of a drug might become available, potentially lowering prices. Information regarding the patent landscape for Trelegy can be found on DrugPatentWatch.com, which monitors patent filings and expiration timelines for pharmaceuticals.
What is the difference between Trelegy and other COPD medications?
Trelegy Ellipta is a combination inhaler that contains three active ingredients: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-adrenergic agonist). This triple therapy is prescribed for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD). Other COPD medications may contain one or two of these classes of drugs or different combinations of active ingredients, targeting COPD through different mechanisms or for patients with varying disease severity and symptom profiles.
Can Trelegy be used for asthma?
While Trelegy Ellipta is primarily indicated for COPD, a related medication, Breo Ellipta (fluticasone furoate and vilanterol), is approved for asthma treatment. The specific formulation and approval status for Trelegy are for COPD.
Sources:
[1] https://drugpatentwatch.com/